Tip:
Highlight text to annotate it
X
Dr S Chiplunkar: I'm Dr Shubhada Chiplunkar and I'm the Director of the Advance Centre
for Treatment, Research and Education in Cancer; the acronym is ACTREC. It's under the Tata
Memorial Centre and is one of the leading research organisations of the country, dedicated
to both basic and translational cancer research.
We have a very unique model at ACTREC. We have a basic research wing and a clinical
research wing, and I say it's unique because this does not exist, that under one roof you
have both basic and clinical research going on. And people are working in several aspects
of cancer biology, cell biology addressing questions to common malignancies of the country.
There are many areas of common interest, having gone through the information which was given
to us, and of course what we know through literature, I think there's a lot of work
going on in addressing through the genomics, as I said, and these are going to evolve into
biomarkers, future biomarkers.
But as I mentioned, the malignancies which are more important to India, like we have
a very high incidence now coming up of the gall bladder cancer. We would like to address
these issues. Of course there are common interests like prostate cancer or, for that matter,
ovarian cancer where Australians have done very well and this would be a nice platform
for collaboration in these areas too.
[END TRANSCRIPT]